Dorothée Duluc

Dr. Dorothée Duluc

Immunology from Concept and Experiments to Translationdisabled, Bordeaux, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Clinical Immunology
Verified
Journal Article
Closed access
DTDelphine Turpin
Delphine Turpin
AFAdeline Furudoi
Adeline Furudoi
MPMarie Parrens
Marie Parrens
PBPatrick Blanco
Patrick Blanco
JVJean-François Viallard
Jean-François Viallard
DDDorothée Duluc
Dorothée Duluc

30 January 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CSCorentin Le Saos-Patrinos
Corentin Le Saos-Patrinos
SLSéverine Loizon
Séverine Loizon
PBPatrick Blanco
Patrick Blanco
JVJean-François Viallard
Jean-François Viallard
DDDorothée Duluc
Dorothée Duluc
Common variable immunodeficiency is the most common clinical primary immunodeficiency in adults. Its hallmarks are hypogammaglobulinemia and compromised B-cell differentiation into memory or antibody-secreting cells leading to recurrent infections. This disease is heterogeneous, with some patients harboring multiple complications such as lymphoproliferative disorders, autoimmune manifestations, or granulomatous inflammation. The mechanisms leading to these complications remain elusive despite numerous associations found in the literature. For instance, although described as a B cell intrinsic disease, numerous abnormalities have been reported in other immune cell compartments. Here, we tuned our attention to follicular helper T cells, a CD4+ T cell population specialized in B cell help, considering the recent publications showing an involvement of these cells in CVID pathogenesis.

30 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAurélien Mattuizzi
Aurélien Mattuizzi
FSFanny Sauvestre
Fanny Sauvestre
TFTiphaine Fargeix
Tiphaine Fargeix
EWEoghann White
Eoghann White
CLClaire Leibler
Claire Leibler
ELEstibaliz Lazaro
Estibaliz Lazaro
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals.

10 January 2017 in Cancer Cell & Microenvironment
Verified
Journal Article
Open access
WYWenjie Yin
Wenjie Yin
DDDorothée Duluc
Dorothée Duluc
HJHyeMee Joo
HyeMee Joo
SOSangKon Oh
SangKon Oh
Dendritic cells (DCs) are major antigen presenting cells that can efficiently prime and activate cellular immune responses. Delivering antigens to in vivo DCs has thus been considered as a promising strategy that could allow us to mount T cell-mediated therapeutic immunity against cancers in patients. Successful development of such types of cancer vaccines that can target in vivo DCs, however, requires a series of outstanding questions that need to be addressed. These include the proper selection of which DC surface receptors, specific DC subsets and DC activators that can further enhance the efficacy of vaccines by promoting effector T cell infiltration and retention in tumors and their actions against tumors. Supplementing these areas of research with additional strategies that can counteract tumor immune evasion mechanisms is also expected to enhance the efficacy of such therapeutic vaccines against cancers. After more than a decade of study, we have concluded that antigen targeting to DCs via CD40 to evoke cellular responses is more efficient than targeting antigens to the same types of DCs via eleven other DC surface receptors tested. In recent work, we have further demonstrated that a prototype vaccine (anti-CD40-HPV16.E6/7, a recombinant fusion protein of anti-human CD40 and HPV16.E6/7 protein) for HPV16-associated cancers can efficiently activate HPV16.E6/7-specific T cells, particularly CD8+ T cells, from the blood of HPV16+ head-and-neck cancer patients. Moreover, anti-CD40-HPV16.E6/7 plus poly(I:C) can mount potent therapeutic immunity against TC-1 tumor expressing HPV16.E6/7 protein in human CD40 transgenic mice. In this manuscript, we thus highlight our recent findings for the development of novel CD40 targeting immunotherapeutic vaccines for HPV16-associated malignancies. In addition, we further discuss several of key questions that still remain to be addressed for enhancing therapeutic immunity elicited by our prototype vaccine against HPV16-associated malignancies.

25 January 2023 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
CSCorentin Le Saos-Patrinos
Corentin Le Saos-Patrinos
SLSéverine Loizon
Séverine Loizon
AZAtika Zouine
Atika Zouine
DTDelphine Turpin
Delphine Turpin
MDMarie-Sarah Dilhuydy
Marie-Sarah Dilhuydy
DDDorothée Duluc
Dorothée Duluc
Chronic lymphocytic leukemia (CLL) is characterized by an expansion of mature B cells in the bone marrow, peripheral lymphoid organs and blood. CD4 T helper (Th) lymphocytes significantly contribute to the physiopathology of CLL, but the subset(s) of Th cell involved in CLL pathogenesis is (are) still under debate. In this study, we performed flow cytometry analysis of the circulatory T cells of untreated CLL patients and observed an increase in follicular helper T cells (Tfh), which is a subset of T cells specialized in B cell help. Elevated numbers of Tfh cells correlated with disease severity as measured by the Binet staging system. Tfh from CLL patients were activated and skewed toward a Th1 profile as evidenced by their PD-1 + IL-21 + IFNγ+ phenotype and their CXCR3 + CCR6- chemokine receptor profile. Tfh efficiently enhanced B-CLL survival and proliferation through IL-21 but independently of IFNγ. Finally, we observed an inverse correlation between the Tfh1 and IgA and IgG serum levels in patients, suggesting a role for this Tfh subset in the immune dysfunction associated with CLL. Altogether, our data highlight an impairment in circulatory Tfh subsets in CLL patients and their critical role in CLL physiopathology.

12 March 2023
Verified
Book Chapter
Closed access
PDF file
PSPauline Santa
Pauline Santa
ARAnaïs Roubertie
Anaïs Roubertie
SLSéverine Loizon
Séverine Loizon
AGAnne Garreau
Anne Garreau
AFAmandine Ferriere
Amandine Ferriere
VSVanja Sisirak
Vanja Sisirak